Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.42 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
| ▸ | ESRRG | P62508 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | USP8 | P40818 | 2/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24268110 | 0.92 | DDR1 (0.40) | MCL1KDM1AKMT2ADDR1PPARD | |
| SCHEMBL23879572 | 0.90 | MCL1 (0.44) | MCL1ACLYKDM1AKMT2ADDR1 | |
| SCHEMBL23879597 | 0.85 | DDR1 (0.40) | DDR1ALDH1A1 | |
| SCHEMBL24268121 | 0.84 | MCL1 (0.40) | MCL1ACLYKDM1AKMT2ADDR1 | |
| SCHEMBL23879530 | 0.83 | ACLY (0.52) | MCL1ACLYKDM1AKMT2AUSP2 | |
| SCHEMBL24268128 | 0.83 | KDM1A (0.49) | MCL1ACLYKDM1ADDR1USP2 | |
| SCHEMBL24268165 | 0.82 | KDM1A (0.51) | MCL1ACLYKDM1AKMT2AALDH1A1 | |
| SCHEMBL23879603 | 0.82 | MCL1 (0.40) | MCL1KDM1AKMT2ADDR1NPC1 | |
| SCHEMBL23879629 | 0.82 | KDM1A (0.50) | MCL1ACLYKDM1AUSP2USP8 | |
| SCHEMBL23879571 | 0.82 | KDM1A (0.50) | MCL1ACLYKDM1AUSP2USP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | MCL1 1929/4885ACLY 2228/4885KDM1A 2735/4885 |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | MCL1 1929/4885ACLY 2228/4885KDM1A 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.